Back to search

Article

Rnf43 Mutation As A Biomarker For Immune Checkpoint Inhibitor Efficacy In Colorectal Cancer

2021-06-02

Abstract excerpt

<h4>Background: </h4> Immune checkpoint inhibitors can prolong the survival of patients with advanced colorectal cancer and have been approved for the treatment of metastatic colorectal cancer patients with mismatch repair defects and high microsatellite instability (dMMR-MSI-H). However, there are still many deficiencies in their clinical application, such as their benefit in a limited population, low efficiency,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c6cd9c46-4662-526c-81bd-1cde5bbf3cd8
DOI
10.21203/rs.3.rs-536739/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Rnf43 Mutation As A Biomarker For Immune Checkpoint Inhibitor Efficacy In Colorectal CancerDOI 10.21203/rs.3.rs-536739/v1
Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.Semantic proximity
A Mutational Signature that Predicts Prognosis and Benefit of Immune Checkpoint Blockade in Colorectal CancerSemantic proximity
Cancer-specific associations of driver genes with immunotherapy outcomeSemantic proximity
Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.Semantic proximity
Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.Semantic proximity
Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancerSemantic proximity
Continuous Prediction for Tumor Mutation Burden Based on Transcriptional Data in Gastrointestinal CancersSemantic proximity
DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint InhibitorsSemantic proximity
Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer.Semantic proximity
LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients.Semantic proximity
Exploration of the role of tumor mutation burden in clinical significance, immunotherapy response predictor and immune cell infiltration in colon cancerSemantic proximity
TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity
Select a neighboring publication to make it the new centre.